668 related articles for article (PubMed ID: 33271260)
1. Novel poly (ADP-ribose) polymerases inhibitor DHC-1 exhibits in vitro and in vivo anticancer activity on BRCA-deficient pancreatic cancer cells.
Wu X; Li Q; Zhang F; Wang L; Wang J; Fan J; Di G; Guo C
Food Chem Toxicol; 2021 Jan; 147():111892. PubMed ID: 33271260
[TBL] [Abstract][Full Text] [Related]
2. A Novel Inhibitor of Poly(
Jin Y; Wang L; Jin C; Zhang N; Shimizu S; Xiao W; Guo C; Liu X; Si H
Chem Res Toxicol; 2024 Apr; 37(4):561-570. PubMed ID: 38534178
[TBL] [Abstract][Full Text] [Related]
3. BTH-8, a novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, causes DNA double-strand breaks and exhibits anticancer activities in vitro and in vivo.
Guo C; Zhang F; Wu X; Yu X; Wu X; Shi D; Wang L
Int J Biol Macromol; 2020 May; 150():238-245. PubMed ID: 32057845
[TBL] [Abstract][Full Text] [Related]
4. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
Clark CC; Weitzel JN; O'Connor TR
Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
[TBL] [Abstract][Full Text] [Related]
6. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
7. Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.
Chen WH; Song SS; Qi MH; Huan XJ; Wang YQ; Jiang H; Ding J; Ren GB; Miao ZH; Li J
Acta Pharmacol Sin; 2017 Nov; 38(11):1521-1532. PubMed ID: 28770827
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
9. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
[TBL] [Abstract][Full Text] [Related]
10. PARP Inhibitor Sensitizes
Kim C; Kim D; Lee DS; Lee S; Yoo C; Kim KP
Anticancer Res; 2023 Dec; 43(12):5523-5534. PubMed ID: 38030179
[TBL] [Abstract][Full Text] [Related]
11. Novel Poly(ADP-ribose) Polymerase-1 Inhibitor DDHCB Inhibits Proliferation of BRCA Mutant Breast Cancer Cell
Wang L; Zhang S; Yu X; Guo C
Chem Res Toxicol; 2020 Jul; 33(7):1874-1881. PubMed ID: 32394702
[TBL] [Abstract][Full Text] [Related]
12. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
Li N; Wang Y; Deng W; Lin SH
Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
[TBL] [Abstract][Full Text] [Related]
13. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
[TBL] [Abstract][Full Text] [Related]
14. Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors.
Yang ZM; Liao XM; Chen Y; Shen YY; Yang XY; Su Y; Sun YM; Gao YL; Ding J; Zhang A; He JX; Miao ZH
Acta Pharmacol Sin; 2017 Jul; 38(7):1038-1047. PubMed ID: 28414200
[TBL] [Abstract][Full Text] [Related]
15. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
[TBL] [Abstract][Full Text] [Related]
16. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.
Wang B; Chu D; Feng Y; Shen Y; Aoyagi-Scharber M; Post LE
J Med Chem; 2016 Jan; 59(1):335-57. PubMed ID: 26652717
[TBL] [Abstract][Full Text] [Related]
17. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
Liu X; Shi Y; Maag DX; Palma JP; Patterson MJ; Ellis PA; Surber BW; Ready DB; Soni NB; Ladror US; Xu AJ; Iyer R; Harlan JE; Solomon LR; Donawho CK; Penning TD; Johnson EF; Shoemaker AR
Clin Cancer Res; 2012 Jan; 18(2):510-23. PubMed ID: 22128301
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.
Wang L; Yang C; Xie C; Jiang J; Gao M; Fu L; Li Y; Bao X; Fu H; Lou L
Cancer Sci; 2019 Mar; 110(3):1064-1075. PubMed ID: 30663191
[TBL] [Abstract][Full Text] [Related]
19. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
20. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Bryant HE; Schultz N; Thomas HD; Parker KM; Flower D; Lopez E; Kyle S; Meuth M; Curtin NJ; Helleday T
Nature; 2005 Apr; 434(7035):913-7. PubMed ID: 15829966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
